Core Viewpoint - The article discusses the performance and business operations of Haiprime, a leading multinational pharmaceutical company, highlighting its revenue structure, market position, and recent financial results. Company Overview - Haiprime, established in 1998 and headquartered in Shenzhen, operates in the heparin industry, biopharmaceutical CDMO, and innovative drug development, aiming to provide high-quality medications globally [2][7]. - The company has a dual financing platform (A+H shares) and focuses on the production and commercialization of heparin and other pharmaceutical products [2][7]. Financial Performance - For the first quarter of 2025, Haiprime reported a revenue of 1.394 billion yuan, representing a year-on-year growth of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up by 1.00% [7]. - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the Chinese yuan [3]. Shareholder Information - As of March 31, 2025, Haiprime had 28,400 shareholders, an increase of 6.00% from the previous period [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On August 12, Haiprime's stock price decreased by 0.53%, with a trading volume of 56.64 million yuan and a market capitalization of 19.178 billion yuan [1]. - The stock's average trading cost is 11.35 yuan, with current price levels between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6]. Institutional Holdings - As of March 31, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Innovation Drug, with both increasing their holdings [8].

Group 1 - The Shanghai Composite Index rose by 0.96%, closing at 3617.6 points, while the Hang Seng Index increased by 0.68%, closing at 24902.53 points [1] - The premium of Haiprui's A-shares over H-shares reached 125.21%, ranking 16th among AH shares [1] - Haiprui's A-shares closed at 13.26 yuan, with a gain of 0.68%, and H-shares closed at 6.43 HKD, up by 3.38% [1] Group 2 - Shenzhen Haiprui Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [1] - The company's main business covers the entire heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [1] - Haiprui's three business segments are synergistic, driven by unmet clinical needs, aiming to provide high-quality, safe, and effective drugs and services to global patients [1]

Group 1 - The Shanghai Composite Index rose by 0.66% to close at 3583.31 points, while the Hang Seng Index increased by 0.92% to 24733.45 points [1] - The premium of Haiprui's A-shares over H-shares reached 131.61%, ranking 14th among AH shares in terms of premium rate [1] - Haiprui's A-shares closed at 13.17 yuan, down 0.6%, and H-shares closed at 6.22 Hong Kong dollars, remaining flat [1] Group 2 - Shenzhen Haiprui Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [1] - The company operates across the entire heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [1] - Haiprui's three business segments are synergistic and driven by unmet clinical needs, aiming to provide high-quality, safe, and effective drugs and services to global patients [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 深圳市海普瑞藥業集團股份有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09989 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

Core Viewpoint - Haiprime, a leading multinational pharmaceutical company, is benefiting from the depreciation of the RMB and its focus on innovative drugs and biopharmaceuticals [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company reported that 93.04% of its revenue comes from overseas, benefiting from the depreciation of the RMB [3]. - As of March 31, 2025, Haiprime's revenue reached 1.394 billion yuan, a year-on-year increase of 1.53%, with a net profit of 157 million yuan, up 1.00% [7]. Financial Performance - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. - The average trading cost of Haiprime's shares is 11.29 yuan, with the current stock price fluctuating between resistance at 13.88 yuan and support at 12.41 yuan [6]. Market Activity - On August 1, Haiprime's stock fell by 1.05%, with a trading volume of 111 million yuan and a turnover rate of 0.66%, bringing the total market capitalization to 19.442 billion yuan [1]. - The main capital flow showed a net outflow of 5.9454 million yuan, indicating a reduction in main capital positions over the past three days [4][5].

Core Viewpoint - The article discusses the performance and business operations of Haiprui, a leading multinational pharmaceutical company, highlighting its revenue structure and market dynamics, particularly in relation to the depreciation of the Chinese yuan and its impact on overseas revenue [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company’s main business revenue composition includes: formulations (56.55%), heparin sodium and low molecular weight heparin raw materials (20.25%), CDMO (19.58%), and others (3.63%) [7]. - As of March 31, 2025, Haiprui reported a revenue of 1.394 billion yuan, a year-on-year increase of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up 1.00% year-on-year [7]. Financial Performance - Haiprui's overseas revenue accounts for 93.04% of its total revenue, benefiting from the depreciation of the yuan [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Dynamics - The stock experienced a decline of 1.40% on July 31, with a trading volume of 152 million yuan and a turnover rate of 0.91%, resulting in a total market capitalization of 19.647 billion yuan [1]. - The stock's average trading cost is 11.28 yuan, with recent buying activity observed, although the buying pressure is not strong [6]. - The stock is currently trading between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6]. Institutional Holdings - As of March 31, 2025, Haiprui's top ten circulating shareholders include Hong Kong Central Clearing Limited and Innovation Drug, with increases in their holdings compared to the previous period [8].

本文源自：金融界 作者：行情君 海普瑞AH溢价达122.85%，位居AH股溢价率第17位。当日收盘，海普瑞A股报13.58元，跌幅0.15%，H 股报6.66港元，下跌2.63%。 资料显示，深圳市海普瑞药业集团股份有限公司于1998年成立于深圳,是拥有A+H双融资平台的领先跨 国制药企业,主要业务覆盖肝素全产业链、生物大分子CDMO和创新药物的投资、开发及商业化。公司 的三大板块业务相互协同,以临床未满足需求为驱动,致力于为全球患者提供高质量的安全有效药物和服 务,护佑健康。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 7月30日，上证指数涨0.17%，收报3615.72点，恒生指数跌1.36%，收报25176.93点。 ...

Group 1 - The A-share innovative drug concept stocks are experiencing a rebound, with notable increases in stock prices [1] - Leyi Group reached the daily limit increase, while Yipinhong surged by 14%, Hite Bio increased by over 13%, and Haipu Rui rose by over 5% [1] - Other companies such as Fuyuan Pharmaceutical, Anglikang, and Shutaishen also saw their stock prices rise [1]

Macro Economy - The Yarlung Tsangpo River downstream hydropower project has officially commenced, with a total investment of approximately 1.2 trillion yuan [1] - The Ministry of Industry and Information Technology (MIIT) announced that a work plan for stabilizing growth in ten key industries, including steel, non-ferrous metals, and petrochemicals, will be released soon [10] Industry News - The State Administration for Market Regulation conducted administrative talks with Ele.me, Meituan, and JD.com, urging them to adhere to relevant laws and regulations and to engage in rational competition [9] - The MIIT is promoting innovation in future industries such as humanoid robots, the metaverse, and brain-computer interfaces, aiming to lay out new fields and tracks [11] - A joint meeting by MIIT, the National Development and Reform Commission, and the State Administration for Market Regulation focused on regulating competition in the new energy vehicle industry [12] Company News - 1,551 A-share listed companies have released their performance forecasts for the first half of 2025, with 26 companies expecting a net profit increase of over 1,000% year-on-year [3] - Yushutech has initiated its listing counseling with CITIC Securities as the counseling institution [14] - China Shipbuilding Industry Corporation has received approval from the China Securities Regulatory Commission for its absorption and merger with China Shipbuilding Heavy Industry Group [16] - Longhua Automobile reported a net profit of 6.337 billion yuan for the first half of 2025, a year-on-year decrease of 10.22% [19] - Haipuri announced that its innovative drug H1710 has completed the first patient enrollment and dosing in Phase I clinical trials [20]

近日，深圳市海普瑞药业集团股份有限公司（以下简称"海普瑞"或"公司"） 自主研发的创新候选药物注射用 H1710（以下简称"H1710"）I 期临床试验已完 成首例受试者入组及首次给药。现将相关情况公告如下： 一、 注射用 H1710 的基本情况 证券代码： 002399 证券简称：海普瑞 公告编号：2025-028 深圳市海普瑞药业集团股份有限公司 关于H1710完成I期临床试验首例受试者入组 及首次给药的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳市海普瑞药业集团股份有限公司 董事会 注射用H1710是一种低抗凝活性的肝素衍生物，是海普瑞自主研发的高效高选 择性的乙酰肝素酶（HPA）抑制剂。乙酰肝素酶在多种恶性肿瘤中高表达，并且与 肿瘤的生长和转移密切相关。H1710通过抑制乙酰肝素酶的活性和表达，展现出抗 肿瘤作用。H1710作为靶向乙酰肝素酶的全新化合物，具有更为合理的链长和独特 的柔性结构，是一种高效、高选择性的乙酰肝素酶抑制剂。 二、 临床试验的相关情况 公司于2025年2月获得国家药品监督管理局核准签发的《药物临床试验批准通 知书》 ...